Lyra Therapeutics, Inc.
NASDAQ:LYRA
0.172 (USD) • At close March 14, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) USD.
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|
| Revenue
| 1.534 | 1.558 | 1.363 | 0.285 | 0 | 0 | 1.244 |
| Cost of Revenue
| 0 | 0 | 1.067 | 1.001 | 0.095 | 0.027 | 0 |
| Gross Profit
| 1.534 | 1.558 | 0.296 | -0.716 | -0.095 | -0.027 | 1.244 |
| Gross Profit Ratio
| 1 | 1 | 0.217 | -2.512 | 0 | 0 | 1 |
| Reseach & Development Expenses
| 43.766 | 48.029 | 38.797 | 29.694 | 12.522 | 12.032 | 4.975 |
| General & Administrative Expenses
| 18.501 | 19.057 | 17.556 | 14.206 | 9.687 | 4.487 | 3.528 |
| Selling & Marketing Expenses
| 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| SG&A
| 18.501 | 19.057 | 17.556 | 14.206 | 9.687 | 4.487 | 3.528 |
| Other Expenses
| 35.615 | 0 | 1.316 | 0 | 0 | 0 | 1.194 |
| Operating Expenses
| 97.882 | 68.678 | 56.353 | 43.9 | 22.209 | 16.519 | 8.503 |
| Operating Income
| -96.348 | -67.12 | -56.306 | -43.615 | -22.209 | -16.519 | -7.259 |
| Operating Income Ratio
| -62.808 | -43.081 | -41.31 | -153.035 | 0 | 0 | -5.835 |
| Total Other Income Expenses Net
| 2.952 | 4.499 | 1.041 | 0.102 | 0.082 | 0.213 | 1.23 |
| Income Before Tax
| -93.396 | -62.621 | -55.265 | -43.513 | -22.127 | -16.306 | -6.029 |
| Income Before Tax Ratio
| -60.884 | -40.193 | -40.547 | -152.677 | 0 | 0 | -4.846 |
| Income Tax Expense
| -0.039 | 0.059 | 0.013 | -1.103 | -0.082 | -0.213 | -1.23 |
| Net Income
| -93.435 | -62.68 | -55.278 | -42.41 | -22.045 | -16.093 | -6.029 |
| Net Income Ratio
| -60.909 | -40.231 | -40.556 | -148.807 | 0 | 0 | -4.846 |
| EPS
| -1.43 | -1.26 | -1.83 | -3.27 | -2.57 | -1.25 | -0.96 |
| EPS Diluted
| -1.43 | -1.26 | -1.83 | -3.27 | -2.57 | -1.25 | -0.96 |
| EBITDA
| -96.348 | -65.25 | -53.923 | -42.614 | -22.114 | -16.492 | -7.177 |
| EBITDA Ratio
| -62.808 | -41.881 | -39.379 | -153.035 | 0 | 0 | -5.769 |